These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 9013373

  • 21. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
    Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR.
    Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
    [Abstract] [Full Text] [Related]

  • 22. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
    Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M.
    Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
    [Abstract] [Full Text] [Related]

  • 23. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
    Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA.
    Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A study of the interaction between dirithromycin and astemizole in healthy adults.
    Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Stotka J, Harris J.
    Am J Ther; 1997 Aug; 4(2-3):73-9. PubMed ID: 10423595
    [Abstract] [Full Text] [Related]

  • 26. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
    Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D.
    Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
    [Abstract] [Full Text] [Related]

  • 27. An in-vitro study on the metabolism of rokitamycin and possible interactions of the drug with rat liver microsomes.
    Zhao XJ, Ishizaki T.
    J Pharm Pharmacol; 1999 Oct; 51(10):1167-74. PubMed ID: 10579688
    [Abstract] [Full Text] [Related]

  • 28. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS, Poku JW, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
    Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI.
    Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
    [Abstract] [Full Text] [Related]

  • 30. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD.
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [Abstract] [Full Text] [Related]

  • 31. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
    Preskorn SH, Alderman J, Greenblatt DJ, Horst WD.
    Psychopharmacol Bull; 1997 Aug; 33(4):659-65. PubMed ID: 9493476
    [Abstract] [Full Text] [Related]

  • 32. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
    Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M.
    Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
    [Abstract] [Full Text] [Related]

  • 33. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.
    Grasela DM, LaCreta FP, Kollia GD, Randall DM, Uderman HD.
    Pharmacotherapy; 2000 Mar; 20(3):330-5. PubMed ID: 10730688
    [Abstract] [Full Text] [Related]

  • 34. Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
    Emoto C, Yamazaki H, Iketaki H, Yamasaki S, Satoh T, Shimizu R, Suzuki S, Shimada N, Nakajima M, Yokoi T.
    Xenobiotica; 2001 May; 31(5):265-75. PubMed ID: 11491388
    [Abstract] [Full Text] [Related]

  • 35. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes.
    Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK.
    Drug Metab Dispos; 1995 Jun; 23(6):631-6. PubMed ID: 7587944
    [Abstract] [Full Text] [Related]

  • 36. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [Abstract] [Full Text] [Related]

  • 37. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA, Wood AJ.
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [Abstract] [Full Text] [Related]

  • 38. Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A.
    Wang JS, Wang W, Xie HG, Huang SL, Zhou HH.
    Br J Clin Pharmacol; 1997 Aug; 44(2):195-8. PubMed ID: 9278210
    [Abstract] [Full Text] [Related]

  • 39. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [Abstract] [Full Text] [Related]

  • 40. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ.
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.